Back to today’s briefing

Story perspectives

Australia Approves Donanemab: Alzheimer’s Breakthrough with Risks

5/27/2025

50 7

Summary

Story summary

Australia has greenlit Donanemab, a groundbreaking monoclonal antibody for Alzheimer’s, after a pivotal trial involving 1,736 participants. While it successfully slowed disease progression by 35%, it fell short in enhancing cognitive function. With potential side effects like brain swelling affecting 24% of users, the annual price tag could reach up to $80,000, awaiting government approval.

1 of 1

Story summary

Australia has greenlit Donanemab, a groundbreaking monoclonal antibody for Alzheimer’s, after a pivotal trial involving 1,736 participants. While it successfully slowed disease progression by 35%, it fell short in enhancing cognitive function. With potential side effects like brain swelling affecting 24% of users, the annual price tag could reach up to $80,000, awaiting government approval.